Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of EQ143 (Aumolertinib) in Healthy Volunteers of Different Ethnicities
NCT04969965Phase 1Completed
- Sponsor
- EQRx
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of almonertinib in non-small cell lung cancer (NSCLC), sponsored by EQRx. Primary endpoint: Plasma Concentration of EQ143 at Day 10. Started Jun 2021; status: completed.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04969965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969965.